First published 10/3/2026, 1:00:15 AM · Last updated 10/3/2026, 1:00:15 AM

P3.12.64 Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation EGFR-TKI Failure: SACHI Study Insights

An Elsevier BV journal article published 2025-10-01 presents SACHI study findings on frontline treatment duration for MET‑amplified non‑small‑cell lung cancer following failure of third‑generation EGFR tyrosine kinase inhibitors. The provided excerpt only lists the publisher and content type and includes no additional study details.

Illustrative image: Non-small-cell_lung_cancer treatment — Ortega, M.A.; Pekarek, L.; Navarro, F.; Fraile-Martínez, O.; García-Montero, C.; Álvarez-Mon, M.Á.; Diez-Pedrero, R.; Boyano-Adánez, M.d.C.; Guijarro, L.G.; Barrena-Blázquez, S./Wikimedia Commons, CC BY 4.0

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 4/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The article presents SACHI study insights about frontline treatment duration for a specific subgroup of NSCLC after third‑generation EGFR‑TKI failure.

Sources

P3.12.64 Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation EGFR-TKI Failure: SACHI Study Insights

Report an issue